Mylan Buys Abbott’s Non-U.S. Generic Drugs Portfolio

July 22, 2014

The deal will cost an estimated $5.3 billion and involve more than 100 products in several key areas.

Pennsylvania-based healthcare company Mylan Inc. has announced the completion of a deal with Abbott Laboratories, which will see Mylan acquiring Abbott's specialty and branded generics business intended for non-U.S. developed markets.

The deal will cost Mylan an estimated $5.3 billion, with the company taking over Abbott's portfolio of more than 100 products in several key areas, including cardiology, metabolic and gastrointestinal conditions. Upon completion of the deal Abbott will get 105 million shares in a new, combined company, which will give it an approximately 21 percent share in Mylan.

The new public company, called Mylan N.V., will be based in the Netherlands, Mylan announced. Thanks to the transaction, the company will instantly boost its market in regions such as Europe, Japan, Australia and New Zealand. Some of the products featured in the portfolio are patent protected, innovative and hard-to-manufacture and are expected to bring extra growth potential to the company. Mylan estimated that the deal could generate an additional $1.9 billion in revenue per year.

According to Mylan's executive chairman Robert J. Coury, the company had been looking at a series of options for further development, but decided on buying Abbott's portfolio because it was considered to be the perfect opportunity to build on the company's momentum, while diversifying its offerings in major markets outside the United States.

Sponsored Recommendations

Choosing The Right Partner for CHIPS Act Investments

As the U.S. looks to invest in the semiconductor research and production using CHIPS Act 2022 funding, it's important to choose the right partner.

EMWD Uses Technology to Meet Sustainability Goals

Eastern Municipal Water District pilots artificial intelligence-enabled control and machine learning to help save energy, reduce costs, and improve quality.

Protein Processing Solutions: Automation & Control

For protein processors looking to address industry challenges, improve efficiency, and stay ahead in a competitive market, Rockwell Automation offers tailored automation, control...

Automotive Manufacturing Innovation: Smart Solutions for a Connected Future

Rockwell Automation provides automation and control systems tailored for the automotive and tire industries, supporting electric vehicle production, tire production, battery production...